It's time to rethink response assessment.

PhasED-Seq delivers early and accurate response assessment using ultra-sensitive ctDNA MRD technology.

"Foresight was the partner we were waiting for due to PhasED-Seq’s robust evidence and reputation as the most reliable and sensitive MRD assay in development for LBCL."

David Chang, M.D., Ph.D.
CEO, Allogene Therapeutics

Ask us about MRD endpoints for your next biopharma clinical trial

30-40% of DLBCL patients are likely to relapse 1-2 years after first-line therapy.1

PhasED-Seq predicts relapse risk immediately at the end of treatment. That's up to 200 days sooner than relying on PET/CT for relapse diagnosis.2

Lower limit of detection. Higher standards.

1 part 

per million




Analytical sensitivity (or limit of detection)2

Confidence level in assay performance3

Clinical sensitivity at EOT2

Clinical specificity at EOT2

From research to diagnostic development

3x faster

Accelerate clinical trials by 12 months with earlier endpoint measurement

Across multiple studies, PhasED-Seq MRD accurately stratified patient response at end of treatment. 3,4

Event-free survival (EFS) with MRD may accelerate clinical trial readouts by up to a year than progression-free survival (PFS) alone.3 

Time to accrue 25% event rate

Read our latest data on the prognistic utility of PhasED-Seq MRD in DLBCL and FL

Download Now

At Foresight, we are raising the bar on what it means to be ‘ultra-sensitive.’ It is not enough to be sensitive. MRD tests must be highly accurate and reliable, with clinical relevance. 

We propose LOD95 as the standard in assay sensitivity. 

The lowest limit detection expected across all clinical samples with a 95% confidence.

PhasED-Seq Assay Performance*

Case Study: Earlier relapse detection in DLBCL

Our Clinical Research Assays

Inquire here

Please contact us for more information on our Solid Tumor Platform

Submit academic research inquiry (Investigator Initiated Research)

Recent Scientific Presentations

10-6 was shown to be the optimal limit of detection for consistent and accurate response assessment across multiple time points before, during, and after therapy.3

PhasED-Seq predicted deep, durable remission to liso-cel as early as fifteen days into treatment.5

© 2024 Foresight Diagnostics, Inc. The tests described have been developed and their performance characteristics have been determined by the CLIA-registered laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). All Rights Reserved.


1. Nuvvula S, Dahiya S, Patel SA. The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(6):362–372. doi: 10.1016/j.clml.2021.11.010

2. Kurtz, et al., Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma, American Society of Hematology Annual Meeting (2023) 

3. Goldstein, et al., Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy, American Society of Hematology Annual Meeting (2023) 

4. Roschevski et al., End of Treatment Response Assessment After Frontline Therapy for Aggressive B-cell Lymphoma: Landmark Comparison of a Singular PET/CT scan vs Ultrasensitive Circulating Tumor DNA, American Society of Hematology Annual Meeting (2023); Sworder, et al., Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World ctDNA Study, American Society of Hematology Annual Meeting (2023) 

5. Stepan, et al., Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study, American Society of Hematology Annual Meeting (2023) 

Want to stay up to date? Join our mailing list for updates on our research and products.

Want to learn more about PhasED-Seq? Register for our free webinar!

Register now

Diffuse Large B-cell Lymphoma (DLBCL)

Follicular Lymphoma

Find more videos on our YouTube

PhasED-Seq Lymphoma Platform

Multiple Myeloma

Hodgkins Lymphoma

*These performance characteristics have not been reviewed by the FDA

PhasED-SeqTM is a liquid-biopsy powered platform that detects minimal residual disease (MRD) from circulating tumor DNA (ctDNA), an early indicator of cancer relapse.